Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09BDK
|
||||
Former ID |
DIB016013
|
||||
Drug Name |
SNG-163
|
||||
Synonyms |
SGIC-163; ER-a36 inhibitor (cancer), Shenogen
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [543898] | ||
Company |
Shenogen Pharma Group Ltd
|
||||
Target and Pathway | |||||
Target(s) | Estrogen receptor | Target Info | Inhibitor | [543898] | |
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
Plasma membrane estrogen receptor signaling | |||||
LKB1 signaling events | |||||
Regulation of Telomerase | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
FOXA1 transcription factor network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.